Skip to main content
Clinical Trials/NCT03447691
NCT03447691UnknownNot Applicable

Comparison Between Volatile Anesthetic-desflurane and Total Intravenous Anesthesia With Propofol and Remifentanil on Early Recovery Quality and Long Term Prognosis of Patients Undergoing Pancreatic Cancer and Common Bile Duct Cancer Surgery

Yonsei University1 site in 1 country132 target enrollmentStarted: August 27, 2017Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Enrollment
132
Locations
1
Primary Endpoint
score of QoR40 (Quality of Recovery 40)

Study Overview

Brief Summary

Investigators asses whether there is any difference in short term recovery and long term prognosis according to the anesthetic method in patients who undergoing pancreatic cancer and bile duct cancer and undergoing surgery for PPPD or distal pancreatectomy.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Other
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Masking Description

  • The investigator who research the QoR-40 questionnaire before and after the surgery will not know which group the patient is assigned to.
  • Because of the difference in anesthesia method, it is impossible to apply blindness to an anesthesiologist practicing anesthesia. Thus, the anesthesiologist will maintain anesthesia with the same target in both groups. (anesthesia depth, hemodynamic status and pain control)
  • Blind is released to investigator and outcomes assessor after completion of QoR-40 questionnaire.

Eligibility Criteria

Ages
20 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients with ASA class I-III who are scheduled to undergo general anesthesia and who are diagnosed with pancreatic cancer or common bile duct cancer and who are scheduled for PPPD or distal pancreatectomy
  • patients who voluntarily agree to participate the clinical study after fully informed and understood about the study

Exclusion Criteria

  • there was distant metastasis at the time of diagnosis
  • history of drug adverse reaction or use of opioid or sedative drugs before the surgery
  • patients who can not communicate enough to answer the survey
  • obesity patients over BMI 30
  • patient who are expected to maintain ventilator care on the first day of post operation due to the difficult to extubation right after the surgery
  • patients who have inappropriate reasons to participate in clinical research

Arms & Interventions

DES Group

Experimental

Desflurane will be administered via tracheal intubation tube at the level of 0.7-1.1 MAC. Remifentanil will be maintained intravenously by continuous infusion rate of 0.01-0.1 mcg / kg / min

DES Group's anesthetic depth will be adjusted to maintain the BIS (Bispectral index) between 40-60. Vital sign will be maintained within the range of ± 20% of the baseline MBP (Mean BP) and HR (Heart Rate).

Intervention: Des (volatile anesthetic-desflurane) (Drug)

TIVA Group

Active Comparator

Propofol and remifentanil will be administered via intravenous, using an infusion pump capable of effect site target controlled infusion.

TIVA Group's anesthetic depth will be adjusted to maintain the BIS (Bispectral index) between 40-60. Vital sign will be maintained within the range of ± 20% of the baseline MBP (Mean BP) and HR (Heart Rate).

Intervention: TIVA (Total intravenous anesthesia with propofol and remifentanil) (Drug)

Outcomes

Primary Outcomes

score of QoR40 (Quality of Recovery 40)

Time Frame: post operative day #3

The QoR-40 consists of a total of 40 questionnaires divided into five categories, it is considered to be the most appropriate index to measure the patient's integrated post operation recovery. Our primary outcome is the score of QoR-40 on the third day after surgery

Secondary Outcomes

  • score of QoR40 (Quality of Recovery 40)(post operative day #7)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials